Manidipino Aurovitas (Manidipine Dihydrochloride)

Manidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, decreasing calcium entry. This causes relaxation of arterial smooth muscle, leading to vasodilation, reduced peripheral resistance, and ultimately a fall in systemic blood pressure.

The appropriate dose of Manidipino Aurovitas is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and any relevant comorbidities. Dosage adjustments are made according to individual therapeutic needs.

Safety data for manidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Manidipine belongs to the dihydropyridine calcium‑channel‑blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or ARBs, it may have a more pronounced effect on peripheral resistance but a lower impact on renin‑angiotensin pathways. Choice of therapy depends on patient profile and comorbid conditions.

Manidipino Aurovitas tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain potency.

The medication is taken orally, usually once daily, with or without food as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as angioedema, and cardiac conduction abnormalities. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe dizziness, or swelling of the face or throat.

Manidipino Aurovitas is contraindicated in patients with known hypersensitivity to manidipine or any component of the formulation, and in individuals with severe aortic stenosis or unstable angina. Caution is also advised for patients with significant hepatic impairment or those taking interacting medications.